Mohammad Sadegh Zia-Ebrahimi is a prominent inventor based in Indianapolis, IN (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of cancer treatments. With a total of 5 patents to his name, Zia-Ebrahimi continues to push the boundaries of medical innovation.

Latest Patents

One of his latest patents focuses on KRas inhibitors. The present invention provides compounds of the formula: KRas G12C inhibitors. This invention includes compounds of Formula I, where R1, R2, and m are as described herein. It also encompasses pharmaceutically acceptable salts of these compounds and methods for using them to treat patients with cancer.

Career Highlights

Zia-Ebrahimi is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His work at Eli Lilly has allowed him to collaborate with some of the brightest minds in the industry, further enhancing his contributions to medical science.

Collaborations

Some of his notable coworkers include David Anthony Barda and Sonia Maria Gutierrez Sanfeliciano. Their collaborative efforts have played a crucial role in advancing research and development in their respective fields.

Conclusion

Mohammad Sadegh Zia-Ebrahimi's innovative work in the pharmaceutical industry exemplifies the impact of dedicated inventors on healthcare. His contributions, particularly in cancer treatment, highlight the importance of ongoing research and collaboration in the pursuit of medical advancements.

This text is generated by artificial intelligence and may not be accurate.